D
Donna Niedzwiecki
Researcher at Duke University
Publications - 391
Citations - 25343
Donna Niedzwiecki is an academic researcher from Duke University. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 77, co-authored 343 publications receiving 22686 citations. Previous affiliations of Donna Niedzwiecki include Yale University & University of Missouri.
Papers
More filters
Journal ArticleDOI
Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781
Joel E. Tepper,Mark J. Krasna,Donna Niedzwiecki,Donna Hollis,Carolyn E. Reed,Richard M. Goldberg,K Kiel,Christopher G. Willett,David J. Sugarbaker,Robert J. Mayer +9 more
TL;DR: The results from this trial reflect a long-term survival advantage with the use of chemoradiotherapy followed by surgery in the treatment of esophageal cancer, and support trimodality therapy as a standard of care for patients with this disease.
Journal ArticleDOI
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy L. Kindler,Donna Niedzwiecki,Donna Hollis,Susan Sutherland,Deborah Schrag,Herbert Hurwitz,Federico Innocenti,Mary F. Mulcahy,Eileen M. O'Reilly,Timothy F. Wozniak,Joel Picus,Pankaj Bhargava,Robert J. Mayer,Richard L. Schilsky,Richard M. Goldberg +14 more
TL;DR: The addition of bevacizumab to gemcitabine does not improve survival in advanced pancreatic cancer patients, and the only statistically significant differences in grades 3 and 4 toxicity occurred for hypertension and proteinuria.
Journal ArticleDOI
Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803
Jeffrey A. Meyerhardt,Denise Heseltine,Donna Niedzwiecki,Donna Hollis,Leonard B. Saltz,Robert J. Mayer,James P. Thomas,Heidi Nelson,Renaud Whittom,Alexander Hantel,Richard L. Schilsky,C. Fuchs +11 more
TL;DR: Beyond surgical resection and postoperative adjuvant chemotherapy for stage III colon cancer, for patients who survive and are recurrence free approximately 6 months after adjuant chemotherapy, physical activity appears to reduce the risk of cancer recurrence and mortality.
Journal ArticleDOI
Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
Edward L. Korn,P. Y. Liu,Sandra J. Lee,Judith Anne W. Chapman,Donna Niedzwiecki,Vera J. Suman,James J. Moon,Vernon K. Sondak,Michael B. Atkins,Elizabeth Eisenhauer,Wendy R. Parulekar,Svetomir N. Markovic,Scott Saxman,John M. Kirkwood +13 more
TL;DR: In this paper, the authors evaluated historical data from cooperative group phase II trials to attempt to develop benchmarks for overall survival (OS) and progression-free survival (PFS) as reference points for future phase II clinical trials.
Journal ArticleDOI
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
Axel Grothey,Alberto Sobrero,Anthony F. Shields,Takayuki Yoshino,James Paul,Julien Taieb,John Souglakos,Qian Shi,Rachel Kerr,Roberto Labianca,Jeffrey A. Meyerhardt,Dewi Vernerey,Takeharu Yamanaka,Ioannis Boukovinas,Jeffrey P. Meyers,Lindsay A. Renfro,Donna Niedzwiecki,Donna Niedzwiecki,Toshiaki Watanabe,Valter Torri,Valter Torri,Mark P Saunders,Daniel J. Sargent,Thierry André,Timothy Iveson +24 more
TL;DR: Among patients with stage III colon cancer receiving adjuvant therapy with FOLFOX or CAPOX, noninferiority of 3 months of therapy, as compared with 6 months, was not confirmed in the overall population.